Therapy Areas: AIDS & HIV
ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months
23 August 2019 - - UK-based specialist HIV company ViiV Healthcare, which is majority owned by UK-based pharmaceutical company GlaxoSmithKline plc (LSE: GSK), with Pfizer Inc. (NYSE: PFE) and Shionogi...
Signant Health names new clinical vice president, Internal Medicine
21 August 2019 - United States-based Signant Health has added Anthony Todd Everhart, MD, FACP to the Signant Health Science and Medicine Team as clinical vice president, Internal Medicine, it was repo...
Ontario Drug Benefit Program to offer eligible HIV patients access to Gilead Sciences Canada's Biktarvy tablets
8 August 2019 - Gilead Sciences Canada, a subsidiary of Gilead Sciences Incorporated, has revealed that the Ontario Drug Benefit Program is offering eligible patients access to Biktarvy (bictegravir 5...
ViiV Healthcare reveals data from phase III TANGO study
26 July 2019 - ViiV Healthcare, a specialist HIV company majority owned by GSK, along with Pfizer Inc and Shionogi Limited as shareholders has revealed data from its phase III TANGO study for treatmen...
Gilead Presents New Findings on Profile of Descovy for Potential Use as HIV Pre-exposure Prophylaxis Compared with Truvada
25 July 2019 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricit...
US Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant
25 July 2019 - - US-based drugmaker Merck (NYSE: MRK) has presented results from a Phase 1 study evaluating the pharmacokinetics and safety of a prototype subdermal drug-eluting implant for extended a...